Skip to main content
Top
Published in: Breast Cancer 5/2017

01-09-2017 | Original Article

Social impacts of the work loss in cancer survivors

Authors: Hideko Yamauchi, Chizuko Nakagawa, Takashi Fukuda

Published in: Breast Cancer | Issue 5/2017

Login to get access

Abstract

Background

As cancer frequently occurs during the most productive years of life, our purpose was to estimate the cost of work loss of cancer survivors and develop interventions to minimize the loss.

Methods

We estimated the cost of the work loss from all cancers resulting from patients’ inpatient, outpatient, and non-treatment days. This was calculated with a new method, the product of the “employment rate coefficient × productivity coefficient,” making use of data published by the Japanese Ministries.

Results

The estimate of work loss on treatment days for all cancers was $1820.21 million in men and $939.38 million in women. In terms of disease classification, lung cancer was the largest cause in men, whereas breast cancer was the largest in women. On non-treatment days, the work losses because of gastric, colon, and lung cancers were large in men, while breast cancer was the largest in women and in total. The estimated loss for all cancers was $3685.506 million in men and $2502.565 million in women, when the product was assumed 0.5.

Conclusions

In Japan, breast cancer was considered the leading cause for cost of work loss, and the most influential cause when the product of the “employment rate coefficient × productivity coefficient” for breast cancer was assumed the same as the product for all other types of cancers. It is necessary to establish support systems for working cancer survivors.
Literature
1.
go back to reference Saika K, Sobue T. Epidemiology of breast cancer in Japan and the US. Japan Med Assoc J. 2009;52(1):39–44. Saika K, Sobue T. Epidemiology of breast cancer in Japan and the US. Japan Med Assoc J. 2009;52(1):39–44.
3.
go back to reference Center for Cancer Control and Information Services, National Cancer Center. Breast cancer morbidity. 2015. http://gdb.ganjoho.jp/graph_db/gdb1?showData=&dataType=30&graphId=101&totalTarget=11&year=2010&years=1975&years=1976&years=1977&years=1978&years=1979&years=1980&years=1981&years=1982&years=1983&years=1984&years=1985&years=1986&years=1987&years=1988&years=1989&years=1990&years=1991&years=1992&years=1993&years=1994&years=1995&years=1996&years=1997&years=1998&years=1999&years=2000&years=2001&years=2002&years=2003&years=2004&years=2005&years=2006&years=2007&years=2008&years=2009&years=2010&ageSybt=0&ageSt=009&ageEd=A85&currentAge=0&smTypes=14&smType=1&sexType=2&stage=0. Accessed Apr 24 2015. Center for Cancer Control and Information Services, National Cancer Center. Breast cancer morbidity. 2015. http://​gdb.​ganjoho.​jp/​graph_​db/​gdb1?​showData=​&​dataType=​30&​graphId=​101&​totalTarget=​11&​year=​2010&​years=​1975&​years=​1976&​years=​1977&​years=​1978&​years=​1979&​years=​1980&​years=​1981&​years=​1982&​years=​1983&​years=​1984&​years=​1985&​years=​1986&​years=​1987&​years=​1988&​years=​1989&​years=​1990&​years=​1991&​years=​1992&​years=​1993&​years=​1994&​years=​1995&​years=​1996&​years=​1997&​years=​1998&​years=​1999&​years=​2000&​years=​2001&​years=​2002&​years=​2003&​years=​2004&​years=​2005&​years=​2006&​years=​2007&​years=​2008&​years=​2009&​years=​2010&​ageSybt=​0&​ageSt=​009&​ageEd=​A85&​currentAge=​0&​smTypes=​14&​smType=​1&​sexType=​2&​stage=​0.​ Accessed Apr 24 2015.
4.
go back to reference Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer. J Clin Oncol. 2004;22(17):3524–30. doi:10.1200/JCO.2004.10.170.CrossRefPubMed Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer. J Clin Oncol. 2004;22(17):3524–30. doi:10.​1200/​JCO.​2004.​10.​170.CrossRefPubMed
6.
10.
go back to reference Zheng Z, Yabroff KR, Guy GP Jr, Li C, Bangegas MP, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. JNCI. 2016;108(5):djv382. doi:10.1093/jnci/djv382.CrossRef Zheng Z, Yabroff KR, Guy GP Jr, Li C, Bangegas MP, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. JNCI. 2016;108(5):djv382. doi:10.​1093/​jnci/​djv382.CrossRef
11.
go back to reference Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology. 2009;48(10):1283–9. doi:10.1093/rheumatology/kep239.CrossRefPubMed Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology. 2009;48(10):1283–9. doi:10.​1093/​rheumatology/​kep239.CrossRefPubMed
12.
go back to reference Burton WN, Chen CY, Conti DJ, Shultz AB, Pransky G, Edington DW. The association of health risks with on-the-job productivity. J Occup Environ Med. 2005;47(8):769–77.CrossRefPubMed Burton WN, Chen CY, Conti DJ, Shultz AB, Pransky G, Edington DW. The association of health risks with on-the-job productivity. J Occup Environ Med. 2005;47(8):769–77.CrossRefPubMed
13.
go back to reference Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med. 2004;46(4):398–412.CrossRefPubMed Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med. 2004;46(4):398–412.CrossRefPubMed
15.
go back to reference van Roijen L, Essink-Bot ML, Koopmanscap MA, Michel BC, Rutten FF. Societal perspective on the burden of migraine in the Netherlands. Pharmacoeconomics. 1995;7(2):170–9.CrossRefPubMed van Roijen L, Essink-Bot ML, Koopmanscap MA, Michel BC, Rutten FF. Societal perspective on the burden of migraine in the Netherlands. Pharmacoeconomics. 1995;7(2):170–9.CrossRefPubMed
Metadata
Title
Social impacts of the work loss in cancer survivors
Authors
Hideko Yamauchi
Chizuko Nakagawa
Takashi Fukuda
Publication date
01-09-2017
Publisher
Springer Japan
Published in
Breast Cancer / Issue 5/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0759-y

Other articles of this Issue 5/2017

Breast Cancer 5/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine